文献速递骨质疏松与钙磷/甲状旁腺糖尿病

罗莫佐单抗改善骨质疏松合并糖尿病女性的组织厚度校正骨小梁评分

Romosozumab Improves Tissue Thickness-Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该研究为ARCH试验的事后分析,纳入基线合并2型糖尿病的绝经后骨质疏松女性,比较罗莫佐单抗12个月序贯阿仑膦酸钠24个月与单用阿仑膦酸钠36个月对腰椎面积骨密度(aBMD)和组织厚度校正骨小梁评分(TBSTT)的影响。结果显示罗莫佐单抗组第12个月腰椎aBMD和TBSTT增益显著大于阿仑膦酸钠组,转用阿仑膦酸钠后增益维持,第24和36个月仍显著优于单用阿仑膦酸钠。

要点

  • 罗莫佐单抗组第12个月腰椎aBMD和TBSTT增益显著大于阿仑膦酸钠组。
  • 转用阿仑膦酸钠后增益维持,第24和36个月仍显著优于单用阿仑膦酸钠。
  • TBSTT百分比变化与腰椎aBMD百分比变化仅弱相关(R²=0.1493和0.0429)。

核心结论

  • 在合并2型糖尿病的绝经后骨质疏松女性中,罗莫佐单抗12个月序贯阿仑膦酸钠24个月较单用阿仑膦酸钠显著改善腰椎aBMD和TBSTT,且改善程度更大,独立于腹部脂肪。
  • 因此,罗莫佐单抗可能改善2型糖尿病患者的骨强度。

研究设计与样本

  • ARCH研究的事后分析,纳入基线合并2型糖尿病且基线和至少1次基线后访视有腰椎DXA扫描的女性。
  • 罗莫佐单抗序贯阿仑膦酸钠组n=165,阿仑膦酸钠序贯阿仑膦酸钠组n=195。
  • 罗莫佐单抗210 mg每月一次用12个月,随后阿仑膦酸钠70 mg每周一次用24个月;对照为阿仑膦酸钠70 mg每周一次用36个月。
  • 在基线及至少1次基线后访视(第12、24和36个月)的腰椎DXA扫描上评估aBMD和TBSTT。

主要发现

  • 罗莫佐单抗组第12个月腰椎aBMD和TBSTT增益显著大于阿仑膦酸钠组。
  • 罗莫佐单抗组的更大增益在转用阿仑膦酸钠后维持,第24和36个月仍显著优于单用阿仑膦酸钠。
  • TBSTT百分比变化与腰椎aBMD百分比变化(基线至第36个月)弱相关:罗莫佐单抗序贯阿仑膦酸钠组R²=0.1493,阿仑膦酸钠序贯阿仑膦酸钠组R²=0.0429。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Trabecular bone score (TBS), a gray-level texture index derived from lumbar spine (LS) dual-energy x-ray absorptiometry (DXA) scans, is decreased in patients with diabetes and is associated with increased fracture risk, independent of areal bone mineral density (aBMD), but potentially influenced by abdominal fat tissue. OBJECTIVE: Evaluate effect of romosozumab (210 mg monthly) for 12 months followed by alendronate (70 mg weekly) for 24 months vs alendronate alone (70 mg weekly) for 36 months on LS aBMD and TBS in women with type 2 diabetes (T2D) enrolled in the ARCH study. METHODS: This post hoc analysis included women from ARCH who had T2D at baseline and LS DXA scans at baseline and ≥1 postbaseline visit (romosozumab-to-alendronate, n = 165; alendronate-to-alendronate, n = 195). aBMD and TBS (determined by an updated tissue thickness-adjusted TBS algorithm [TBSTT]) were assessed on LS DXA scans at baseline and ≥1 postbaseline visit (months 12, 24, and 36). RESULTS: Romosozumab led to significantly greater gains in LS aBMD and TBSTT at month 12 vs alendronate, and the greater gains with romosozumab were maintained after transition to alendronate and persisted significantly at months 24 and 36 vs alendronate alone. TBSTT percentage changes weakly correlated to LS aBMD percentage changes from baseline to month 36 (romosozumab-to-alendronate, R2 = 0.1493; alendronate-to-alendronate, R2 = 0.0429). CONCLUSION: In postmenopausal women with osteoporosis and T2D, 12 months of romosozumab followed by 24 months of alendronate vs alendronate alone significantly improved LS aBMD and TBSTT (independently of abdominal fat) and to a greater extent. Hence, romosozumab may improve bone strength in patients with T2D. TRIAL REGISTRATION: ClinicalTrials.gov-NCT01631214.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ferrari S, Betah D, Feldman RG, et al. Romosozumab Improves Tissue Thickness-Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes. J Clin Endocrinol Metab. 2025. PMID: 39854280. doi:10.1210/clinem/dgae862

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。